{"id":"NCT01287117","sponsor":"Genentech, Inc.","briefTitle":"A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment","officialTitle":"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2011-02-01","resultsPosted":"2013-10-18","lastUpdate":"2013-11-27"},"enrollment":319,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Urticaria"],"interventions":[{"type":"DRUG","name":"Omalizumab","otherNames":["Xolair"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Omalizumab 75 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 150 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 300 mg","type":"EXPERIMENTAL"}],"summary":"The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dose H1 antihistamine treatment.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in the Weekly Itch Severity Score","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-3.63,"sd":5.22},{"arm":"Omalizumab 75 mg","deltaMin":-6.46,"sd":6.14},{"arm":"Omalizumab 150 mg","deltaMin":-6.66,"sd":6.28},{"arm":"Omalizumab 300 mg","deltaMin":-9.4,"sd":5.73}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"},{"comp":"OG000 vs OG002","p":"0.0012"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":18},"locations":{"siteCount":66,"countries":["United States","Denmark","France","Germany","Italy","Poland","Spain","Turkey (Türkiye)"]},"refs":{"pmids":["39193419","29655772","28390587","27939380","27540466","27424128","26054553","25046337"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":80},"commonTop":["Nasopharyngitis","Idiopathic urticaria","Headache","Urticaria","Sinusitis"]}}